EyePoint Pharmaceuticals (EYPT) Misses Q1 EPS by 17c

EyePoint Pharmaceuticals (NASDAQ: EYPT) reported Q1 EPS of ($0.99), $0.17 worse than the analyst estimate of ($0.82). Revenue for the quarter came in at $696 thousand versus the consensus estimate of $1.01 million.

For earnings history and earnings-related data on EyePoint Pharmaceuticals (EYPT) click here.

You May Also Be Interested In

• Anthropic plans IPO potentially exceeding SpaceX's $86B record - Bloomberg
• Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
• Freedom Broker Upgrades John B. Sanfilippo & Son, Inc. (JBSS) to Buy